Monday, August 16, 2010

Report: FDA is Investigating Whether GlaxoSmithKline Held Back Avandia Data - Health Blog - WSJ

Just when you thought there was nothing new to say about Avandia, Time magazine reports — citing deputy FDA commissioner Josh Sharfstein — that the agency is investigating whether Glaxo broke the law by holding back from the FDA data indicating the drug carried an increased risk of heart attacks.

Posted via email from Jack's posterous

1 comment:

Anonymous said...

If Glaxo withheld any information this would require the FDA to remove Avandia from the market.